Acta Anaesthesiol Scand:产妇发生意外硬脊膜穿刺后的慢性疼痛:一项病例对照前瞻性观察研究

2022-01-09 “罂粟花”公众号 “罂粟花”公众号

背景

背景

本研究调查产程中意外硬脊膜穿刺后硬脊膜穿刺后头痛(PDPH)妇女慢性头痛和背痛的发生率。

方法

评估产后18-24个月慢性头痛、背痛和残疾的发生率。将接受硬膜外血补片(PDPH-EBP)治疗的PDPH患者与无硬膜外血补片的PDPH患者(PDPH-NO EBP)、单纯硬膜外镇痛患者和无硬膜外镇痛患者进行配对。本研究的主要结果是慢性头痛和背痛的发生率。次要结果是硬膜外补血对慢性疼痛发展的影响。本研究使用卡方检验或 Fisher's检验来计算优势比。

结果

两组之间的人口统计特征没有统计学意义。在非硬膜外组中,没有女性发生慢性头痛,2/116例(1.7%)发生慢性背痛。在无并发症的硬膜外组中,无女性发生慢性头痛,7/116(6.0%例)报告慢性背痛。在PDPH-NO EBP组中,9/56(16.1%)妇女报告慢性头痛,10/56(17.9%)报告慢性背痛。PDPH-EBP组慢性头痛12/59例(20.3%),慢性腰背痛14/59例(23.7%)。无硬膜外或无并发症硬膜外组无残疾报告(慢性疼痛评分为3或4)。PDPH-no EBP组和PDPH-EBP组分别有8.9%和8.4%的女性报告高度残疾。

结论

患有PDPH的女性有较高的慢性头痛、背痛和残疾的发生率。本研究发现保守治疗和EBP治疗的患者在慢性疼痛发展方面的差异没有统计学意义

原始出处:

Binyamin Y, Heesen P, Orbach- Zinger S, et al. Chronic pain in parturients with an accidental dural puncture: A case- controlled prospective observational study. Acta Anaesthesiol Scand. 2021;00:1– 8.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775621, encodeId=990f1e75621da, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Feb 15 01:28:25 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756181, encodeId=344b1e5618120, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Jun 13 20:28:25 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688994, encodeId=3cdf16889949a, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Tue Mar 08 03:28:25 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850142, encodeId=f26418501422a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Apr 06 19:28:25 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051748, encodeId=d31f2051e48fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon May 02 05:28:25 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006547, encodeId=c600200654e7e, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Aug 18 04:28:25 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801380, encodeId=b452180138048, content=<a href='/topic/show?id=addfe36175d' target=_blank style='color:#2F92EE;'>#硬脊膜穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73617, encryptionId=addfe36175d, topicName=硬脊膜穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 14 12:28:25 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633622, encodeId=cd081633622f1, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Mar 07 05:28:25 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260080, encodeId=5146126008056, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311974, encodeId=6b6313119e4a0, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-02-15 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775621, encodeId=990f1e75621da, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Feb 15 01:28:25 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756181, encodeId=344b1e5618120, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Jun 13 20:28:25 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688994, encodeId=3cdf16889949a, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Tue Mar 08 03:28:25 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850142, encodeId=f26418501422a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Apr 06 19:28:25 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051748, encodeId=d31f2051e48fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon May 02 05:28:25 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006547, encodeId=c600200654e7e, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Aug 18 04:28:25 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801380, encodeId=b452180138048, content=<a href='/topic/show?id=addfe36175d' target=_blank style='color:#2F92EE;'>#硬脊膜穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73617, encryptionId=addfe36175d, topicName=硬脊膜穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 14 12:28:25 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633622, encodeId=cd081633622f1, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Mar 07 05:28:25 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260080, encodeId=5146126008056, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311974, encodeId=6b6313119e4a0, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-06-13 xugc
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775621, encodeId=990f1e75621da, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Feb 15 01:28:25 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756181, encodeId=344b1e5618120, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Jun 13 20:28:25 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688994, encodeId=3cdf16889949a, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Tue Mar 08 03:28:25 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850142, encodeId=f26418501422a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Apr 06 19:28:25 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051748, encodeId=d31f2051e48fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon May 02 05:28:25 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006547, encodeId=c600200654e7e, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Aug 18 04:28:25 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801380, encodeId=b452180138048, content=<a href='/topic/show?id=addfe36175d' target=_blank style='color:#2F92EE;'>#硬脊膜穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73617, encryptionId=addfe36175d, topicName=硬脊膜穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 14 12:28:25 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633622, encodeId=cd081633622f1, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Mar 07 05:28:25 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260080, encodeId=5146126008056, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311974, encodeId=6b6313119e4a0, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1775621, encodeId=990f1e75621da, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Feb 15 01:28:25 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756181, encodeId=344b1e5618120, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Jun 13 20:28:25 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688994, encodeId=3cdf16889949a, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Tue Mar 08 03:28:25 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850142, encodeId=f26418501422a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Apr 06 19:28:25 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051748, encodeId=d31f2051e48fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon May 02 05:28:25 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006547, encodeId=c600200654e7e, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Aug 18 04:28:25 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801380, encodeId=b452180138048, content=<a href='/topic/show?id=addfe36175d' target=_blank style='color:#2F92EE;'>#硬脊膜穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73617, encryptionId=addfe36175d, topicName=硬脊膜穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 14 12:28:25 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633622, encodeId=cd081633622f1, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Mar 07 05:28:25 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260080, encodeId=5146126008056, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311974, encodeId=6b6313119e4a0, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-04-06 windight
  5. [GetPortalCommentsPageByObjectIdResponse(id=1775621, encodeId=990f1e75621da, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Feb 15 01:28:25 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756181, encodeId=344b1e5618120, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Jun 13 20:28:25 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688994, encodeId=3cdf16889949a, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Tue Mar 08 03:28:25 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850142, encodeId=f26418501422a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Apr 06 19:28:25 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051748, encodeId=d31f2051e48fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon May 02 05:28:25 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006547, encodeId=c600200654e7e, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Aug 18 04:28:25 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801380, encodeId=b452180138048, content=<a href='/topic/show?id=addfe36175d' target=_blank style='color:#2F92EE;'>#硬脊膜穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73617, encryptionId=addfe36175d, topicName=硬脊膜穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 14 12:28:25 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633622, encodeId=cd081633622f1, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Mar 07 05:28:25 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260080, encodeId=5146126008056, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311974, encodeId=6b6313119e4a0, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1775621, encodeId=990f1e75621da, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Feb 15 01:28:25 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756181, encodeId=344b1e5618120, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Jun 13 20:28:25 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688994, encodeId=3cdf16889949a, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Tue Mar 08 03:28:25 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850142, encodeId=f26418501422a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Apr 06 19:28:25 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051748, encodeId=d31f2051e48fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon May 02 05:28:25 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006547, encodeId=c600200654e7e, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Aug 18 04:28:25 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801380, encodeId=b452180138048, content=<a href='/topic/show?id=addfe36175d' target=_blank style='color:#2F92EE;'>#硬脊膜穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73617, encryptionId=addfe36175d, topicName=硬脊膜穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 14 12:28:25 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633622, encodeId=cd081633622f1, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Mar 07 05:28:25 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260080, encodeId=5146126008056, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311974, encodeId=6b6313119e4a0, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1775621, encodeId=990f1e75621da, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Feb 15 01:28:25 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756181, encodeId=344b1e5618120, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Jun 13 20:28:25 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688994, encodeId=3cdf16889949a, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Tue Mar 08 03:28:25 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850142, encodeId=f26418501422a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Apr 06 19:28:25 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051748, encodeId=d31f2051e48fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon May 02 05:28:25 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006547, encodeId=c600200654e7e, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Aug 18 04:28:25 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801380, encodeId=b452180138048, content=<a href='/topic/show?id=addfe36175d' target=_blank style='color:#2F92EE;'>#硬脊膜穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73617, encryptionId=addfe36175d, topicName=硬脊膜穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 14 12:28:25 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633622, encodeId=cd081633622f1, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Mar 07 05:28:25 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260080, encodeId=5146126008056, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311974, encodeId=6b6313119e4a0, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1775621, encodeId=990f1e75621da, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Feb 15 01:28:25 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756181, encodeId=344b1e5618120, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Jun 13 20:28:25 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688994, encodeId=3cdf16889949a, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Tue Mar 08 03:28:25 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850142, encodeId=f26418501422a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Apr 06 19:28:25 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051748, encodeId=d31f2051e48fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon May 02 05:28:25 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006547, encodeId=c600200654e7e, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Aug 18 04:28:25 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801380, encodeId=b452180138048, content=<a href='/topic/show?id=addfe36175d' target=_blank style='color:#2F92EE;'>#硬脊膜穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73617, encryptionId=addfe36175d, topicName=硬脊膜穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 14 12:28:25 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633622, encodeId=cd081633622f1, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Mar 07 05:28:25 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260080, encodeId=5146126008056, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311974, encodeId=6b6313119e4a0, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-03-07 爆笑小医
  9. [GetPortalCommentsPageByObjectIdResponse(id=1775621, encodeId=990f1e75621da, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Feb 15 01:28:25 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756181, encodeId=344b1e5618120, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Jun 13 20:28:25 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688994, encodeId=3cdf16889949a, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Tue Mar 08 03:28:25 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850142, encodeId=f26418501422a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Apr 06 19:28:25 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051748, encodeId=d31f2051e48fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon May 02 05:28:25 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006547, encodeId=c600200654e7e, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Aug 18 04:28:25 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801380, encodeId=b452180138048, content=<a href='/topic/show?id=addfe36175d' target=_blank style='color:#2F92EE;'>#硬脊膜穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73617, encryptionId=addfe36175d, topicName=硬脊膜穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 14 12:28:25 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633622, encodeId=cd081633622f1, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Mar 07 05:28:25 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260080, encodeId=5146126008056, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311974, encodeId=6b6313119e4a0, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1775621, encodeId=990f1e75621da, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Feb 15 01:28:25 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756181, encodeId=344b1e5618120, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Jun 13 20:28:25 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688994, encodeId=3cdf16889949a, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Tue Mar 08 03:28:25 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850142, encodeId=f26418501422a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Apr 06 19:28:25 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051748, encodeId=d31f2051e48fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon May 02 05:28:25 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006547, encodeId=c600200654e7e, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Aug 18 04:28:25 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801380, encodeId=b452180138048, content=<a href='/topic/show?id=addfe36175d' target=_blank style='color:#2F92EE;'>#硬脊膜穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73617, encryptionId=addfe36175d, topicName=硬脊膜穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 14 12:28:25 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633622, encodeId=cd081633622f1, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Mar 07 05:28:25 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260080, encodeId=5146126008056, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311974, encodeId=6b6313119e4a0, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 08:28:25 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-01-11 rgjl

相关资讯

Anesth Analg:氯胺酮注射液治疗慢性疼痛:随机对照试验的系统回顾和荟萃分析

静脉注射氯胺酮广泛用于治疗慢性疼痛患者,但其长期影响尚不确定。我们综合了来自随机对照试验的数据,以研究静脉输注氯胺酮缓解慢性疼痛的有效性,并确定是否有任何疼痛分类或治疗方案与更大的益处相关。